Impact on progression-free survival of adjuvant @entity786 , @entity1891 , XXXX ( @entity632 ), and @entity2699 (CYVADIC) chemotherapy for @entity7996 . A prospective trial.

@entity632 @entity1 @entity2699 @entity242 @entity5 @entity786 @entity1891 @entity7996 @entity1370 @entity2359
To assess the impact on progression-free survival of the use of the multiagent chemotherapy regimen of @entity786 , @entity1891 , @entity632 ( @entity632 ), and @entity2699 (CYVADIC) as adjuvant treatment for @entity1 with @entity7996 : 20 evaluable @entity1 who underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy for @entity7996 received adjuvant multiagent chemotherapy with @entity1891 1 mg/m2 days 1 and 4, @entity632 ( @entity632 ) 40 mg/m2 and @entity786 400 mg/m2 day 2, and @entity2699 200 mg/m2 days 1 through 4 for a total of 9 monthly cycles or until recurrence of disease was documented. @entity1 were followed for a median of 65 months (range: 5-116 months). Myelotoxicity was monitored by weekly complete blood counts, @entity1370 by monthly radionuclide angiography, and @entity2359 by monthly physical examination. Survival and progression-free survival were calculated by the method of Kaplan and Meier (17). The Fisher exact test was employed to determine the significance of recurrence rates between histologic groups (18). These 20 @entity1 received 172 of a planned 180 cycles of chemotherapy. Dose reductions in response to myelotoxicity were necessitated in four cycles among three @entity1 . Mild @entity2359 was observed in six @entity1 (30%) and moderate @entity2359 in one @entity1 (5%). A decrease in cardiac ejection fraction of > 10% was observed in two @entity1 (10%). No deaths ascribable to complications arising from chemotherapy were observed. Seven @entity1 (35%) developed recurrence of disease. Recurrence rates for pure @entity242 and mixed @entity5 did not differ significantly (P = .65). Progression-free survival for the population at 2 years was 80% and at 5 years was 65%. This study describes the largest prospective trial of adjuvant combination chemotherapy for @entity1 with @entity7996 reported to date. Adjuvant chemotherapy employing the combination of @entity786 , @entity1891 , @entity632 ( @entity632 ), and @entity2699 (CYVADIC) failed to impact significantly on long-term survival in this group of @entity1 with @entity7996 .
